Yep, two nice points called out:
1. ”Dr McKibbon says Botanix doesn’t need the dosh - one-third of which is not drawn downimmediately - for its current Sofdra roll-out in the US.“But if an acquisition opportunity emerges, it does not have to hinge on a capital raising,”he says. “It allows us to be nimble.”
2. “Meanwhile, three months after the US Sofdra launch, prescriptions have exceededmanagement’s expectations.“
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 31.0¢ | 29.5¢ | $2.519M | 8.363M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 255404 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 226506 | 5 |
View Market Depth
| Last trade - 16.11pm 23/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |